» Articles » PMID: 29044445

Development of a Screening Test for Cognitive Impairment in Alcoholic Population: TEDCA

Overview
Specialty Psychiatry
Date 2017 Oct 19
PMID 29044445
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Several studies have found cognitive impairment in patients with a history of alcohol use disorder, affecting their psychosocial functioning and the achievement of therapeutic goals. In order to identify these effects, several cognitive screening tests have been used, though they were not specific for alcoholic population, possibly leading to an increase in the risk of error.

Objective: The aim of this study is to assess the main cognitive deficits in patients with history of alcohol use disorders, through the development of a specific screening test for alcohol-related cognitive impairment.

Methodology: The TEDCA (Test of detection of cognitive impairment in alcoholism) was designed based on three dimensions: Visuospatial Cognition, Memory / Learning and Executive Function. The study was divided in two phases: During phase 1, test items with greater capacity for discrimination between patients with different levels of cognitive impairment were selected, and during phase 2, the analysis for validity and reliability indexes took place. The sample consisted of 248 participants, 88 controls (phase 2) and 160 patients (phase 1: n=70 and phase 2: n=90).

Results: TEDCA test obtained a high reliability (Cronbach’s alpha 0.754) value and the factor analysis confirmed the presence of the three dimensions previously defined. The present screening tool also discriminated between patients and control group, together with a good diagnostic validity of cognitive impairment.

Conclusions: TEDCA is a new screening test, which identifies the possible presence of cognitive impairment in patients with a history of alcohol use disorders, which can be used in the fields of psychiatry, primary care and research.

Citing Articles

Cognitive impairment in alcohol use disorder and clinical practice guidelines for management of long-stay alcohol use disorder patients.

Praharaj S, Menon V, Ameen S Indian J Psychiatry. 2025; 67(1):144-157.

PMID: 40046491 PMC: 11878472. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_692_24.


Divergent Roles of APOAI and APOM in the Identification of Alcohol Use Disorder and Their Association With Inflammation and Cognitive Decline: A Pilot Study.

Escudero B, Lopez-Valencia L, Arias Horcajadas F, Orio L Int J Neuropsychopharmacol. 2024; 27(7).

PMID: 38970624 PMC: 11287869. DOI: 10.1093/ijnp/pyae029.


Reelin Plasma Levels Identify Cognitive Decline in Alcohol Use Disorder Patients During Early Abstinence: The Influence of APOE4 Expression.

Escudero B, Moya M, Lopez-Valencia L, Arias F, Orio L Int J Neuropsychopharmacol. 2023; 26(8):545-556.

PMID: 37350760 PMC: 10464928. DOI: 10.1093/ijnp/pyad034.


Informing the development of diagnostic criteria for differential diagnosis of alcohol-related cognitive impairment (ARCI) among heavy drinkers: A systematic scoping review.

Jones L, Owens L, Thompson A, Gilmore I, Richardson P PLoS One. 2023; 18(2):e0280749.

PMID: 36753517 PMC: 9907814. DOI: 10.1371/journal.pone.0280749.


Applicability of the ACE-III and RBANS Cognitive Tests for the Detection of Alcohol-Related Brain Damage.

Brown P, Heirene R, Gareth-Roderique-Davies , John B, Evans J Front Psychol. 2019; 10:2636.

PMID: 31849759 PMC: 6892773. DOI: 10.3389/fpsyg.2019.02636.